Safety of glucocorticoids - Clinical trials

Clinical and Experimental Rheumatology

Volumn 29, Issue 5 SUPPL. 68, 2011, Pages

  Da Silva, J A P ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Clinical trials; Glucocorticoids; Safety; Steroids; Toxicit

Indexed keywords

CYCLOSPORIN; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE;

ADVERSE OUTCOME; ARTICLE; ATHEROSCLEROSIS; BONE NECROSIS; CARDIOVASCULAR DISEASE; CHRONOTHERAPY; CLINICAL TRIAL (TOPIC); CUSHINGOID SYNDROME; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG INTOXICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FRACTURE; GLAUCOMA; GLUCOSE INTOLERANCE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; LOW DRUG DOSE; MYOPATHY; OSTEOPOROSIS; PEPTIC ULCER; PRIORITY JOURNAL; PSYCHOSIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; WITHDRAWAL SYNDROME;

GLUCOCORTICOIDS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHEUMATIC DISEASES; RISK FACTORS;

EID: 81155148733     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. DA SILVA JAP, JACOBS JWG, KIRWAN JR JR. et al.: Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006; 65: 285-93. (Pubitemid 43268214)
2. SOLOMON DH, GOODSON NJ, KATZ JN et al.: Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1608-12. (Pubitemid 44799673)
3. NURMOHAMED MT: Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev 2009; 8: 663-7.
4. KLARENBEEK NB, VAN DER KOOIJ SM, HUIZINGA TJW et al.: Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Ann Rheum Dis 2010; 69: 1342-5.
5. PANOULAS VF, METSIOS GS, PACE AV et al.: Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 1286-98.
6. HOOYMAN JR, MELTON LJ 3RD, NELSON AM, O'FALLON WM, RIGGS BL: Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum 1984; 27: 1353-61. (Pubitemid 15190899)
7. SPECTOR TD, HALL GM, MCCLOSKEY EV, KANIS JA: Risk of vertebral fracture in women with rheumatoid arthritis. BMJ 1993; 306: 558. (Pubitemid 23056878)
8. HOES JN, VAN DER GOES MC, VAN RAALTE DH et al.: Glucose tolerance, insulin sensitivity and beta-cell function in rheumatoid arthritis patients treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis In Press.
9. ROIFMAN I, BECK PL, ANDERSON TJ, EISENBERG MJ, GENEST J: Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol 2011; 27: 174-82.
10. KAMEN DL, ALELE JD: Skeletal manifestations of systemic autoimmune diseases. Curr Opin Endocrinol Diabetes Obes 2010; 17: 540-5.
11. HUBER AM, GABOURY I, CABRAL DA et al.: Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders. Arthritis Care Res (Hoboken) 2010; 62: 516-26.
12. VAN DER GOES MC, JACOBS JW, BOERS M et al.: Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010; 69: 1913-9.
13. SVENSSON B, BOONEN A, ALBERTSSON K et al.; FOR THE BARFOT STUDY GROUP: Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate. A two-year randomized trial. Arthritis Rheum 2005; 52: 3360-70. (Pubitemid 41612202)
14. CHOY EHS, SMITH CM, FAREWELL V et al.; FOR THE CARDERA (COMBINATION ANTI-RHEUMATIC DRUGS IN EARLY RHEUMATOID ARHRITIS) TRIAL GROUP: Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 2008; 67: 656-63. (Pubitemid 351571930)
15. DUREZ P, MALGHEM J, TOUKAP AN et al.: Treatment of early rheumatoid arthritis a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 2007; 56: 3919-27. (Pubitemid 350262784)
16. ENGVALL I-L, SVENSSON B, TENGSTRAND B et al.; for THE BARFOT STUDY GROUP: Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study. Arthritis Res Titer 2008; 10: R128
17. MÜLER-YÜKSEL, BIJSTERBOSCH J, GOEKOOP-RUITERMAN YPM et al.: Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 2008; 67: 823-8. (Pubitemid 351829383)
18. REID DM, DEVOGELAER JP, SAAG K et al.: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373: 1253-63.
19. SANCHEZ-GUERRERO J, FRAGOSO-LOYO HE, NEUWELT CM et al.: Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. J Rheumatol 2008; 35: 1567-75.
20. HAFSTRÖM I, ROHANI M, DENEBERG S, WÖRNERT M, JOGESTRAND T, FROSTEGÅRD J: Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis - a randomized study. J Rheumatol 2007; 34; 1810-6. (Pubitemid 350067638)
21. RUYSSEN-WITRAND A, FAUTREL B, SARAUX A, LE-LOËT X, PHAM T: Infections induced by low-dose corticosteroids in rheumatoid arthritis: A systematic literature review. Joint Bone Spine 2010; 77: 246-51.
22. STUCK AE, MINDER CE, FREY FJ: Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11:954-63.
23. ALTEN R, DÖRING G, CUTOLO M et al.: Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with night time-release prednisone. J Rheumatol 2010; 37; 2025-31.
24. BUTTGEREIT F, DOERING G, SCHAEFFLER A et al.: Efficacy of modified-release versus standard prednisone to reduce duration of morning stiff ness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008; 371: 205-14.
25. NAGASAWA K, TADA Y, KOARADA S et al.: Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant. Lupus 2006; 15: 354-7. (Pubitemid 44032710)
26. SMOLEN JS, LANDEWÉ R, BREEDVEL FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
27. TENGSTRAND B, LARSSON E, KLARESKOG L, HAFSTROM I: Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density. Scand J Rheumatol 2007;36:351-8. (Pubitemid 350034806)
28. PINCUS T, SWEARINGEN CJ, LUTA G, SOKKA T: Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial. Ann Rheum Dis 2009; 68: 1715-20.
29. HELLGREN K, ILIADOU A, ROSENQUIST R et al.: Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case-control study. Ann Rheum Dis 2010; 69: 654-9.